Work

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.511

Authors: Matt D. Galsky, Abdel Saci, Peter Szabo, Li Wang, Jun Zhu, Alex Azrilevich, Bruce S. Fischer, Andrea Necchi, Arlene O. Siefker-Radtke, Padmanee Sharma

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb (United States), Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2790752991

Cites:

Cited by: 8

Related to: 10